0 137

Cited 6 times in

Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small cell lung cancer

Authors
 Zang, Dae Young  ;  Lee, Kyoo Hyung  ;  Lee, Jung Shin  ;  Lee, Je Hwan  ;  Kim, Woo Kun  ;  Kim, Sang-Hee  ;  Kim, Won Dong  ;  Kim, Dong Soon  ;  Kim, Joo Hang  ;  Kim, Byung Soo  ;  Cho, Yong-Baik  ;  Kim, Dae-Kee  ;  Kim, Key H 
Citation
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.22(5) : 495-498, 1999 
Journal Title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
ISSN
 0277-3732 
Issue Date
1999
MeSH
Adult ; Aged ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/therapeutic use* ; Carcinoma, Small Cell/drug therapy* ; Carcinoma, Small Cell/mortality ; Female ; Hematologic Diseases/chemically induced ; Humans ; Korea/epidemiology ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/mortality ; Male ; Malonates/chemistry ; Malonates/therapeutic use* ; Middle Aged ; Nausea/diagnosis ; Organoplatinum Compounds/chemistry ; Organoplatinum Compounds/therapeutic use* ; Survival Rate
Abstract
A phase II trial of a novel platinum analog, SKI 2053R, was performed in patients with previously untreated extensive-stage disease (ED) small-cell lung cancer (SCLC). SKI 2053R was administered at the dose of 400 mg/m2 every 3 to 4 weeks as a 1-h infusion. After the first cycle, the dose was escalated to 440 mg/m2 based on toxicity. Thirty-eight patients (31 male) were enrolled between June 1995 and August 1997. The median age was 61 years (range, 36-70 years). Six of 37 evaluable patients achieved a partial response (16.2%; 95% confidence interval [CI], 4.4-28.0%). The durations of response were 1.1, 1.5, 1.7, 1.9, 3.4, and 4.6 months. The estimated median survival time was 7.4 months (95% CI, 5.1-9.7 months). Grade 3 or 4 toxicities were not observed. Grade 1 to 2 leukopenia, anemia, and thrombocytopenia were seen in 5 of 68 cycles, 16 of 68, and 2 of 68, respectively. Nonhematologic toxicities included grade 1 to 2 nausea or vomiting (30 of 68 cycles), nephrotoxicity (27 of 68), and hepatotoxicity (13 of 68). SKI 2053R showed a modest antitumor activity with limited toxicities in patients with ED SCLC. Further clinical trials are warranted in SCLC with a higher dose of SKI 2053R.
Full Text
https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-199910000-00015&LSLINK=80&D=ovft
DOI
10.1097/00000421-199910000-00015
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/172601
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links